TrialDiabetes care2014

Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.

Ronnie Aronson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.